Abstracts tagged "Biomarkers"

Abstract Number: 1333 • ACR Convergence 2022
Patient Perceptions of Rheumatoid Arthritis Blood Work: A Cross-sectional Survey in the ArthritisPower Registry
William Nowell¹, Shilpa Venkatachalam², Kelly Gavigan¹, Michael George³, Johanna Withers⁴, Laura Stradford⁵, Esteban Rivera¹ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Scipher Medicine Corportaion, Waltham, MA, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Although patients' (pts) perspective on disease-related lab testing and its role in treatment decision-making has been examined for some chronic illnesses, ranging from diabetes…
Abstract Number: 1517 • ACR Convergence 2022
Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain
Nelly Ziade¹, Avin Maroof², Antonella Abi Najm¹, Torsten Witte³ and Xenofon Baraliakos⁴, ¹Saint-Joseph University, Beirut, Lebanon, ²Rizgary Teaching Hospital - Erbil, Erbil, Iraq, ³MH-Hannover, Hannover, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with axial spondyloarthritis (axSpA) are diagnosed late, partially due to the absence of a reliable biomarker. The diagnostic value of the anti-CD74 antibodies…
Abstract Number: 1746 • ACR Convergence 2022
Increased CD39+FoxP3+CD4+ Regulatory T Cells in Early Rheumatoid Arthritis Provide a Slot for Prompt Initiation of Methotrexate and Serve as Early Biomarkers of Clinical Response
María-Eugenia Miranda-Carús¹, Alejandro Villalba¹, Laura Nuño¹, Marta Benito-Miguel², Irene Monjo¹, Marta Novella-Navarro¹, Diana Peiteado¹, Sara Garcia-Carazo¹ and Alejandro Balsa³, ¹Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ²Universidad Nebrija, Physiology, Madrid, Spain, ³Hospital La Paz Institute for Health Research, Madrid, Spain
Background/Purpose: FoxP3+ regulatory CD4+ T cells (Tregs) are key to the homeostasis of the immune system. Stressed cells at inflammatory foci release adenine nucleotides to…
Abstract Number: 1914 • ACR Convergence 2022
Acoustic Classification of Early and Advanced Osteoarthritis of the Knee in Clinical Settings
Dave Ewart¹, Ashley Draisey², Omer Inan³, Chris Nichols³ and Goktug Ozmen³, ¹Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, ²Allina Health, Minneapolis, MN, ³Georgia Institute of Technology, Atlanta, GA
Background/Purpose: Knee osteoarthritis (OA) is a prevalent and debilitating disease. Diagnosis of early knee OA is difficult and insensitive with current technologies. The human knee…
Abstract Number: 2135 • ACR Convergence 2022
Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis
James C Waddington¹, Ruoyi Zhou¹, Orla Coleman¹, Bruna Wundervald², Andrew Parnell³, Vinod Chandran⁴, Lara Fallon⁵, Douglass Chapman⁶, Remy Pollock⁷, Shibing Deng⁸, Oliver FitzGerald⁹, Stephen R Pennington¹⁰ and Philip J Mease¹¹, ¹Atturos, Dublin, Ireland, ²Atturos/Hamilton Institute, Maynooth University, Dublin, Ireland, ³Hamilton Institute, Maynooth University, Kildare, Ireland, ⁴Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Pfizer Inc, Montréal, QC, Canada, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Canada ULC, Kirkland QC, Canada, ⁸Pfizer Inc, Waterford, MI, ⁹Conway Institute, University College Dublin, Dublin, Ireland, ¹⁰Atturos/Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ¹¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA.1,2 Using two mass spectrometry (MS)-based proteomic approaches (targeted multiple reaction monitoring [MRM]…
Abstract Number: 0043 • ACR Convergence 2022
Non-invasive Tape Strip Gene Expression Profiling of Lesional Juvenile Dermatomyositis Skin Identifies Immunoregulatory Module That Associates with Skin, Muscle and Global Disease Activity
Jessica Turnier¹, Celine Berthier², Madison McClune², Sarah Vandenbergen², Johann Gudjonsson², Alex Tsoi² and J. Michelle Kahlenberg², ¹University of Michigan, Saline, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) frequently persists even in the absence of active muscle disease. Tape stripping is a non-invasive skin sampling method…
Abstract Number: 0341 • ACR Convergence 2022
Clinical Applications of Urine SERPINC1/ORM1 in MRL-lpr Lupus Nephritis-Prone Mice
YoungEun Kim¹, Eun-Ju Lee¹, Soo Min Ahn¹, Ji Seon Oh², Seokchan Hong¹, Chang Keun Lee¹, Bin Yoo¹ and Yong Gil Kim¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Despite improvements in the treatment of lupus nephritis (LN), the prognosis remains unsatisfactory, and a need for non-invasive biomarkers for early detection endures. Previously,…
Abstract Number: 0595 • ACR Convergence 2022
Validation of Urotensin-2 mRNA Expression as Marker for Tocilizumab Non-Response in Early Rheumatoid Arthritis
Janani Sundaresan¹, Ittai B. Muller¹, Marry Lin¹, Floris P.J.G. Lafeber², Paco Welsing², Maurits C.F.J. De Rotte³, Maja Bulatovic-Calasan⁴, Conny van der Laken⁵, Robert De Jonge⁶ and Gerrit Jansen⁵, ¹Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Clinical Chemistry, Amsterdam University Medical Centers – location AMC, Amsterdam, Netherlands, ⁴Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUmc, Amsterdam, The Netherlands; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ⁶Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Tocilizumab (TCZ), a biologic Disease Modifying Anti-Rheumatic Drug, elicits an immune-modulating effect by binding to the interleukin 6 receptor and inhibiting downstream signaling. Despite…
Abstract Number: 0830 • ACR Convergence 2022
Lymphopenia as a Marker of Disease Activity and Severity in Sarcoidosis
Michael Manansala, Christian Ascoli and Nadera Sweiss, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by granuloma formation. Clinical manifestations are heterogenous, but most commonly affect the pulmonary system. Current biomarkers lack…
Abstract Number: 1048 • ACR Convergence 2022
Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study
Jacqueline Lemmers¹, Arjan van Caam², Brigit Kersten², Els Ende, van den², Hanneke KNAAPEN², Arie Dijk, van², Wanda Hagmolen of ten Have², Frank van den Hoogen², Hans Koenen², Sander van Leuven³, wynand Alkema⁴, Ruben Smeets² and Madelon Vonk⁵, ¹Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³Radboud University, Nijmegen, Netherlands, ⁴Hanze University, Groningen the Netherlands, Dept. Data Science for Life Sciences & Health, Groningen, Netherlands, ⁵Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of death in Systemic Sclerosis (SSc). Early detection and treatment of PH in SSc is…
Abstract Number: 1389 • ACR Convergence 2022
The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors
Patrick Garnero¹, Evelyne Gineyts¹, Jean-Charles Rousseau¹, Pascal Richette², Jérémie SELLAM³ and Roland Chapurlat¹, ¹INSERM 1033, Lyon, France, ²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ³Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France
Background/Purpose: The prognosis of rheumatoid arthritis (RA) is highly variable across patients (P.) and difficult to predict. Usual risk factors, e.g., radiological joint damage, increased…
Abstract Number: 1519 • ACR Convergence 2022
Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI
Erin Chew¹, Sarah Wood¹, Bibin Varghese¹, Christopher Chew², erin wilfong¹ and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Primary heart involvement in systemic sclerosis (SSc-pHI) is characterized by myocardial inflammation with resultant fibrosis that is not secondary to ischemic heart disease or…
Abstract Number: 1747 • ACR Convergence 2022
Changes in the Number and Phenotype of Citrullinated-Antigen Specific T Cells Correlate with Treatment Outcome in Seropositive Rheumatoid Arthritis
Cliff Rims¹, Virginia Muir¹, Anne Hocking¹, Sylvia Posso¹, Heather Bukiri², Jeffrey Carlin³, Bernard Ng⁴, Peter Linsley¹, Eddie James⁵ and Jane Buckner⁵, ¹Benaroya Research Institute, Seattle, WA, ²University of California Los Angeles, Los Angeles, CA, ³Virginia Mason Medical Center, Seattle, WA, ⁴VA Puget Sound HCS, Seattle, WA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: In Rheumatoid arthritis (RA) citrullinated antigen reactive T cells are key drivers of disease, but knowledge about their relative number and phenotype remains limited.…
Abstract Number: 1962 • ACR Convergence 2022
Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Daniel Kass¹, Mehdi Nouraie¹, Yingze Zhang¹, Bryant England², Ted Mikuls³, Gail Kerr⁴, Andreas Reimold⁵, Kevin Gibson¹, Marilyn Glassberg⁶, Paul Dellaripa⁷, Tracy Doyle⁷, Chester Oddis⁸ and Dana Ascherman⁸, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵North Texas Veterans Administration Health Care System, Dallas, TX, ⁶Loyola University Chicago Stritch School of Medicine, Chicago, IL, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Previous studies have demonstrated clinical, epidemiologic, histopathologic, and genetic overlap between advanced rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Corresponding…
Abstract Number: 2148 • ACR Convergence 2022
Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Biomarker of Clinical Response to IL-17 Blockade in Psoriatic Arthritis
Mathias Cardner¹, Danny Tuckwell², Anna Kostikova², Pascal Forrer³, Richard Siegel², Alain Marti³, Marc Vandemeulebroecke³ and Enrico Ferrero², ¹Novartis Global Drug Development and Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Novartis Global Drug Development, Basel, Switzerland
Background/Purpose: Despite several effective targeted therapies, biomarkers that predict whether a patient with psoriatic arthritis (PsA) will respond to a particular treatment are currently lacking.Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].